

Figure S1. Change in lipofuscin autofluorescence with age. Representative confocal images are shown from four experiments. Synchronized late L4/early young adult worms were plated on FUDR containing SA-OP50-seeded NGM plates and worms were maintained at 20°C. Every fifth day, 10-15 worms were mounted onto 2% agar pads and anesthetized with 3 mM levamisole in DMSO. Representative confocal images of each treatment condition were captured through Plan-Aprochromat 20x objective on an LSM510 confocal microscope (Carl Zeiss MicroImaging, Inc) scanning every 200 nm for XZ sections. Images were processed with the Zeiss LSM Image Browser. Figure S1 relates to manuscript figure 1C and 3D.




Figure S2. SA extends the lifespan of daf-16 gene knockout mutant strain. (A) Kaplan-Meier survival curves depicting effects of SA administration on daf-16 gene knockout mutant strain. Starting at day 1 of adulthood, animals were transferred to OP50-seeded NGM-SA plates every 2 days. Survival was assessed every 2 days until all the worms died. (B) Summary of SA treated daf-16 knockout mutant median lifespans. SA increased maximum and median lifespan in daf-16 knockout worms. Data are expressed as means \pm SEM from four independent experiments. *P < 0.01 as compared to vehicle control. Figure S2 relates to manuscript figure 3B.




Figure S3. SA does not attenuate sir-2.1 mRNA levels. Real-time RT-PCR quantification of sir-2.1 in wild-type N2 nematodes treated with increasing doses of SA. Data are expressed as means \pm SEM from five independent experiments. P = 0.08 and P = 0.2, respectively.




Figure S4. Gene Ontology enrichment via WEBGESTALT. Pathway analysis of SA-mediated genomic changes in day 15 N2 WT worms. To further explore the genomic effects of SA administration on N2 WT worms, Gene Ontology (GO) enrichment was performed using WebGestalt, an approach which incorporates information from different public resources and provides graphical depiction of large gene sets from functional genomic, proteomic, and large-scale genetic studies. Biological relationships among Directed acyclic graphs (DAG) were generated using GOView, a web-based application to allow users to visualize and compare multiple provided GO term lists to identify common and specific biological themes. DAG of Group I genes upregulated by SA administration. Chart highlights the metabolic process, lipid metabolic process, and proteolysis pathways among many others as being altered favorably by SA administration.

Supplemental Table 1. Lipid metabolism genes Identified by GO/WebGestalt analysis.

Lipid Metabolic Process			ID: GO: 0006629
Gene Symbol	Gene Name	EntrezGene	Ensembl
Y65B4BR.1	Protein Y65B4BR.1	190488	CELE_Y65B4BR.1
W02B12.1	Protein W02B12.1	174746	CELE_W02B12.1
F28H7.3	Protein F28H7.3	179490	CELE_F28H7.3
Y54G2A.45	Protein Y54G2A.45	3896802	CELE_ Y54G2A.45

List of lipid metabolism genes identified by Gene Ontology/WebGestalt analysis that are significantly upregulated by salicylamine treatment. This is the subset of genes most likely to represent downstream targets of *ets-7*.

Supplemental Table 2. Metabolic process genes Identified by GO/WebGestalt analysis.

Metabolic Process			ID: GO: 0008152
Gene Symbol	Gene Name	EntrezGene	Ensembl
Y65B4BR.1	Protein	190488	CELE_Y65B4BR.1
	Y65B4BR.1		
pcp-2	Protein PCP-2	177741	CELE_F23B2.12
W02B12.1	Protein	174746	CELE_ W02B12.1
	W02B12.1		
ets-7	Protein ETS-7	184687	CELE_F19F10.5
Y54G2A.45	Protein	3896802	CELE_Y54G2A.45
	Y54G2A.45		
smd-1	Protein SMD-1	173269	CELE_F47G4.7
F13D12.6	Protein F13D12.6	174802	CELE_F13D12.6
F28H7.3	Protein	179490	CELE_ F28H7.3
	F28H7.3		
K10C2.3	Protein K10C2.3	180917	CELE_K10C2.3

The larger list of genes exhibiting significant changes with salicylamine treatment, and reorganized as representing metabolic processes more broadly by GO/WebGestalt. Notably, this list includes all of the genes in Supplemental T1 and captures *ets-7* itself.